ANTIPYRINE CLEARANCE AND METABOLITE EXCRETION IN PATIENTS WITH CHRONIC HEPATITIS-C

被引:13
作者
ALI, HA
ELYAZIGI, A
SIECK, JO
ALI, MA
RAINES, DA
SAOUR, J
ERNST, P
KHAN, B
DOSSING, M
机构
[1] BISPEBJERG HOSP, DEPT MED P, DK-2400 COPENHAGEN NV, DENMARK
[2] KING FAISAL SPECIALIST HOSP & RES CTR, DEPT MED, RIYADH 11211, SAUDI ARABIA
[3] KING FAISAL SPECIALIST HOSP & RES CTR, DEPT BIOL & MED RES, RIYADH 11211, SAUDI ARABIA
[4] KING FAISAL SPECIALIST HOSP & RES CTR, DEPT PATHOL & LAB MED, RIYADH 11211, SAUDI ARABIA
[5] KING FAISAL SPECIALIST HOSP & RES CTR, DEPT ONCOL, RIYADH 11211, SAUDI ARABIA
[6] KING FAISAL SPECIALIST HOSP & RES CTR, DEPT BIOSTAT, RIYADH 11211, SAUDI ARABIA
关键词
CHRONIC HEPATITIS C; DRUG CLEARANCE; DRUG METABOLISM; METABOLITES;
D O I
10.1016/0168-8278(95)80254-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Our aim was to study whether chronic hepatitis C affects the Methods: We measured antipyrine clearance from saliva as well as urinary excretion of its main metabolites 4-hydroxy-antipyrine, 3-hydroxy-methyl-antipyrine, and nor-antipyrine in 24 patients with chronic hepatitis C and in 21 healthy control subjects. Due to incomplete urine collection, 12 liver patients and three controls were excluded. Results: Antipyrine clearance (mean+/-SD) was significantly lower in patients with chronic hepatitis C, 1.2+/-0.7 l.h(-1) (n=12), than in controls (n=18), 2.2+/-1.0 l.h(-1) (p=0.006), The urinary excretion of each of the metabolites was depressed to an equal extent in liver patients, The severity of the liver disease, as assessed by Child Pugh score, serum albumin and bilirubin, correlated significantly with antipyrine clearance and urinary excretion of the metabolite 3-hydroxy-methyl-antipyrine . The hepatitis activity index (Knodell) correlated with 3-hydroxy-methyl-antipyrine and 4-hydroxy-antipyrine, only. Conclusions: Moderate-severe chronic hepatitis C does not seem to depress the three main metabolic pathways of antipyrine differently.
引用
收藏
页码:17 / 21
页数:5
相关论文
共 18 条
[11]   THE EFFECT OF SPIRONOLACTONE ON THE LIVER MICROSOMAL-ENZYME SYSTEM IN PATIENTS [J].
OHNHAUS, EE ;
GERBERTARAS, E .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 17 (04) :485-486
[12]   THE DISPOSITION OF ANTIPYRINE AND ITS METABOLITES IN YOUNG AND ELDERLY HEALTHY-VOLUNTEERS [J].
POSNER, J ;
DANHOF, M ;
TEUNISSEN, MWE ;
BREIMER, DD ;
WHITEMAN, PD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 24 (01) :51-55
[13]   ANTIPYRINE AS A MODEL-DRUG TO STUDY HEPATIC DRUG-METABOLIZING CAPACITY [J].
POULSEN, HE ;
LOFT, S .
JOURNAL OF HEPATOLOGY, 1988, 6 (03) :374-382
[14]   ELIMINATION OF ANTIPYRINE AND ITS METABOLITES IN INTERFERON-TREATED HEPATITIS-C [J].
SIECK, JO ;
ELYAZIGI, A ;
ALI, H ;
DOSSING, M ;
SAOUR, J ;
RAINES, DA ;
ERNST, P .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1994, 13 (09) :598-601
[15]   ANTIPYRINE CLEARANCE AND METABOLITE FORMATION IN PATIENTS WITH ALCOHOLIC CIRRHOSIS [J].
TEUNISSEN, MWE ;
SPOELSTRA, P ;
KOCH, CW ;
WEEDA, B ;
VANDUYN, W ;
JANSSENS, AR ;
BREIMER, DD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (05) :707-715
[16]   AUTOMATED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF ANTIPYRINE AND ITS MAIN METABOLITES IN PLASMA, SALIVA AND URINE, INCLUDING 4,4'-DIHYDROXY-ANTIPYRINE [J].
TEUNISSEN, MWE ;
MEERBURGVANDERTORREN, JE ;
VERMEULEN, NPE ;
BREIMER, DD .
JOURNAL OF CHROMATOGRAPHY, 1983, 278 (02) :367-378
[17]  
VESELL ES, 1979, CLIN PHARMACOL THER, V26, P275
[18]  
VESTAL RE, 1975, CLIN PHARMACOL THER, V18, P425